SPOTLIGHT: New data on Actemra

Roche's RA drug Actemra showed equal efficacy rates when compared with other anti-TNF therapies in a late-stage trial, according to researchers. About 58 percent of the patients taking the drug had a 20 percent improvement in their condition, a significant drop from the 74 percent of patients who marked similar progress in a mid-stage trial. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.